Vivace Therapeutics
San Mateo, US · 2 known investors
Vivace Therapeutics is an oncology-focused drug discovery and development company creating small-molecule inhibitors targeting the Hippo-YAP pathway to treat cancers including mesothelioma, meningioma, and various other tumor types. The company adopts a capital-efficient approach to advance novel cancer therapeutics, with potential applications also in fibrotic disease.
BiotechHealthtechMedical Devices
Founders & leadership
<
<UNKNOWN>
Investors · 2
In the news
- Funding Roundup: Recent Financing Rounds Completed for Pain, Cancer, and Musculoskeletal Care Innovations | PharmExecpharmexec.com · 2026
- Vivace Therapeutics Secures $35M in Series D to Advance Cancer Drug VT3989technews180.com · 2025
- Vivace Therapeutics raises $35 million to push mesothelioma drug toward late-stage trial - San Francisco Business Timesbizjournals.com · 2025
- Vivace Therapeutics Raises $35 Million in Series D Financing to Support Clinical Development of First-in-Class Cancer Drug Targeting the Hippo Pathwayprnewswire.com · 2025
- Vivace Therapeutics - 2026 Funding Rounds & List of Investors - Tracxntracxn.com · 2021
- Vivace Therapeutics Raises $40M in Series A and Series B Funding - FinSMEsfinsmes.com · 2017